

Vimpat[®] (lacosamide) – First-time generic

- On May 23, 2022, Alkem launched an <u>AA-rated</u> generic version of UCB's <u>Vimpat (lacosamide)</u> oral solution.
- Vimpat is approved for the treatment of partial-onset seizures in patients 1 month of age and older, and as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older.
- Lacosamide is also available as a generic oral capsule and generic intravenous solution.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.